|
1
|
Wu J, Sun H, Li J, Guo Y, Zhang K, Lang C,
Zou C and Ma H: Increased survival of patients aged 0–29 years with
osteosarcoma: A period analysis, 1984–2013. Cancer Med.
7:3652–3661. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hattinger CM, Patrizio MP, Magagnoli F,
Luppi S and Serra M: An update on emerging drugs in osteosarcoma:
Towards tailored therapies? Expert Opin Emerg Drug. 24:153–171.
2019. View Article : Google Scholar
|
|
3
|
Inui M, Martello G and Piccolo S: MicroRNA
control of signal transduction. Nat Rev Mol Cell Biol. 11:252–263.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li Q, Wang M, Wang N, Wang J, Qi L and Mao
P: Downregulation of microRNA-216b contributes to glioma cell
growth and migration by promoting AEG-1-mediated signaling. Biomed
Pharmacother. 104:420–426. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Azevedo-Pouly AC, Sutaria DS, Jiang J,
Elgamal OA, Amari F, Allard D, Grippo PJ, Coppola V and Schmittgen
TD: miR-216 and miR-217 expression is reduced in transgenic mouse
models of pancreatic adenocarcinoma, knockout of miR-216/miR-217
host gene is embryonic lethal. Funct Integr Genomics. 17:203–212.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jana S, Sengupta S, Biswas S, Chatterjee
A, Roy H and Bhattacharyya A: miR-216b suppresses breast cancer
growth and metastasis by targeting SDCBP. Biochem Biophys Res
Commun. 482:126–133. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen X, Zhang L, Song Q and Chen Z:
MicroRNA-216b regulates cell proliferation, invasion and cycle
progression via interaction with cyclin T2 in gastric cancer.
Anticancer Drugs. 31:623–631. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang W, Guo Z, Yu H and Fan L: miR-216b
inhibits osteosarcoma cell proliferation, migration, and invasion
by targeting Forkhead Box M1. J Cell Biochem. 120:5435–5443. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zheng WW, Zhou J, Zhang CH and Liu XS:
MicroRNA-216b is downregulated in hepatocellular carcinoma and
inhibits HepG2 cell growth by targeting Forkhead box protein M1.
Eur Rev Med Pharmacol Sci. 20:2541–2550. 2016.PubMed/NCBI
|
|
10
|
He S, Liao B, Deng Y, Su C, Tuo J, Liu J,
Yao S and Xu L: miR-216b inhibits cell proliferation by targeting
FOXM1 in cervical cancer cells and is associated with better
prognosis. BMC Cancer. 17:6732017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sandu C, Ngounou Wetie AG, Darie CC and
Steller H: Thiostrepton, a natural compound that triggers heat
shock response and apoptosis in human cancer cells: A proteomics
investigation. Adv Exp Med Biol. 806:443–451. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kwok JM, Myatt SS, Marson CM, Coombes RC,
Constantinidou D and Lam EW: Thiostrepton selectively targets
breast cancer cells through inhibition of forkhead box M1
expression. Mol Cancer Ther. 7:2022–2032. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kongsema M, Wongkhieo S, Khongkow M, Lam
EW, Boonnoy P, Vongsangnak W and Wong-Ekkabut J: Molecular
mechanism of Forkhead box M1 inhibition by thiostrepton in breast
cancer cells. Oncol Rep. 42:953–962. 2019.PubMed/NCBI
|
|
14
|
Huang TH, Wu ATH, Cheng TS, Lin KT, Lai
CJ, Hsieh HW, Chang PM, Wu CW, Huang CF and Chen KY: In silico
identification of thiostrepton as an inhibitor of cancer stem cell
growth and an enhancer for chemotherapy in non-small-cell lung
cancer. J Cell Mol Med. 23:8184–8195. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kalathil D, Prasad M, Chelladurai M, John
S and Nair AS: Thiostrepton degrades mutant p53 by eliciting an
autophagic response in SW480 cells. J Cell Physiol. 233:6938–6950.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Maekawa A, Kohashi K, Kuda M, Iura K,
Ishii T, Endo M, Nakatsura T, Iwamoto Y and Oda Y: Prognostic
significance of FOXM1 expression and antitumor effect of FOXM1
inhibition in synovial sarcomas. BMC Cancer. 16:5112016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Christensen L, Joo J, Lee S, Wai D, Triche
TJ and May WA: FOXM1 is an oncogenic mediator in Ewing Sarcoma.
PLoS One. 8:e545562013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sengupta A, Rahman M, Mateo-Lozano S,
Tirado OM and Notario V: The dual inhibitory effect of thiostrepton
on FoxM1 and EWS/FLI1 provides a novel therapeutic option for
Ewing's sarcoma. Int J Oncol. 43:803–812. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Palmerini E, Torricelli E, Cascinu S,
Pierini M, De Paolis M, Donati D, Cesari M, Longhi A, Abate M,
Paioli A, et al: Is there a role for chemotherapy after local
relapse in high-grade osteosarcoma? Pediatr Blood Cancer.
66:e277922019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li W and Zhang S: Survival of patients
with primary osteosarcoma and lung metastases. J BUON.
23:1500–1504. 2018.PubMed/NCBI
|
|
22
|
Grimer RJ, Taminiau AM and Cannon SR;
Surgical Subcommitte of the European Osteosarcoma Intergroup, :
Surgical outcomes in osteosarcoma. J Bone Joint Surg Br.
84:395–400. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang JY, Yang Y, Ma Y, Wang F, Xue A, Zhu
J, Yang H, Chen Q, Chen M, Ye L, et al: Potential regulatory role
of lncRNA-miRNA-mRNA axis in osteosarcoma. Biomed Pharmacother.
121:1096272020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rickel K, Fang F and Tao J: Molecular
genetics of osteosarcoma. Bone. 102:69–79. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Laoukili J, Stahl M and Medema RH: FoxM1:
At the crossroads of ageing and cancer. Biochim Biophys Acta.
1775:92–102. 2007.PubMed/NCBI
|
|
26
|
Pilarsky C, Wenzig M, Specht T, Saeger HD
and Grutzmann R: Identification and validation of commonly
overexpressed genes in solid tumors by comparison of microarray
data. Neoplasia. 6:744–750. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gentles AJ, Newman AM, Liu CL, Bratman SV,
Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD, et al: The
prognostic landscape of genes and infiltrating immune cells across
human cancers. Nat Med. 21:938–945. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Halasi M and Gartel AL: FOX(M1) news-it is
cancer. Mol Cancer Ther. 12:245–254. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gartel AL: FOXM1 in cancer: Interactions
and vulnerabilities. Cancer Res. 77:3135–3139. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bhat UG, Jagadeeswaran R, Halasi M and
Gartel AL: Nucleophosmin interacts with FOXM1 and modulates the
level and localization of FOXM1 in human cancer cells. J Biol Chem.
286:41425–41433. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Umeh-Garcia M, Simion C, Ho PY, Batra N,
Berg AL, Carraway KL, Yu A and Sweeney C: A Novel bioengineered
miR-127 prodrug suppresses the growth and metastatic potential of
triple-negative breast cancer cells. Cancer Res. 80:418–429. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gong HL, Tao Y, Mao XZ, Song DY, You D and
Ni JD: MicroRNA-29a suppresses the invasion and migration of
osteosarcoma cells by regulating the SOCS1/NF-κB signalling pathway
through negatively targeting DNMT3B. Int J Mol Med. 44:1219–1232.
2019.PubMed/NCBI
|
|
33
|
Patil SL, Palat A, Pan Y, Rajapakshe K,
Mirchandani R, Bondesson M, Yustein JT, Coarfa C and Gunaratne PH:
MicroRNA-509-3p inhibits cellular migration, invasion, and
proliferation, and sensitizes osteosarcoma to cisplatin. Sci Rep.
9:190892019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen D, Liu D and Chen Z: Potential
therapeutic implications of miRNAs in osteosarcoma chemotherapy.
Tumour Biol. 39:10104283177057622017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jana S, Krishna M, Singhal J, Horne D,
Awasthi S, Salgia R and Singhal SS: Therapeutic targeting of
miRNA-216b in cancer. Cancer Lett. 484:16–28. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wu X, Chen W, Cai H, Hu J, Wu B, Jiang Y,
Chen X, Sun D and An Y: miR-216b inhibits pancreatic cancer cell
progression and promotes apoptosis by down-regulating KRAS. Arch
Med Sci. 14:1321–1332. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang Y, Dong D, Jiang S, Zhang E, Zheng W,
Mao L, Li W, Zhou J, Fan L, Cheng R, et al: miR-216b
post-transcriptionally downregulates oncogene KRAS and inhibits
cell proliferation and invasion in clear cell renal cell carcinoma.
Cell Physiol Biochem. 49:1755–1765. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen X, Liu X, He B, Pan Y, Sun H, Xu T,
Hu X and Wang S: miR-216b functions as a tumor suppressor by
targeting HMGB1-mediated JAK2/STAT3 signaling way in colorectal
cancer. Am J Cancer Res. 7:2051–2069. 2017.PubMed/NCBI
|
|
39
|
Wang L, Wang Y, Du X, Yao Y, Wang L and
Jia Y: miR-216b suppresses cell proliferation, migration, invasion,
and epithelial-mesenchymal transition by regulating FOXM1
expression in human non-small cell lung cancer. Onco Targets Ther.
12:2999–3009. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu S, Dong H, Dai H, Liu D and Wang Z:
MicroRNA-216b regulated proliferation and invasion of non-small
cell lung cancer by targeting SOX9. Oncol Lett. 15:10077–10083.
2018.PubMed/NCBI
|
|
41
|
Zheng L, Zhang X, Yang F, Zhu J, Zhou P,
Yu F, Hou L, Xiao L, He Q and Wang B: Regulation of the P2X7R by
microRNA-216b in human breast cancer. Biochem Biophys Res Commun.
452:197–204. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bhat UG, Halasi M and Gartel AL: FoxM1 is
a general target for proteasome inhibitors. PLoS One. 4:e65932009.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hegde NS, Sanders DA, Rodriguez R and
Balasubramanian S: The transcription factor FOXM1 is a cellular
target of the natural product thiostrepton. Nat Chem. 3:725–731.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gartel AL: Thiostrepton, proteasome
inhibitors and FOXM1. Cell Cycle. 10:4341–4342. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Koo CY, Muir KW and Lam EW: FOXM1: From
cancer initiation to progression and treatment. Biochim Biophys
Acta. 1819:28–37. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ahmed M, Uddin S, Hussain AR, Alyan A,
Jehan Z, Al-Dayel F, Al-Nuaim A, Al-Sobhi S, Amin T, Bavi P and
Al-Kuraya KS: FoxM1 and its association with matrix
metalloproteinases (MMP) signaling pathway in papillary thyroid
carcinoma. J Clin Endocrinol Metab. 97:E1–E13. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Halasi M, Schraufnagel DP and Gartel AL:
Wild-type p53 protects normal cells against apoptosis induced by
thiostrepton. Cell Cycle. 8:2850–2851. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wang M and Gartel AL: Micelle-encapsulated
thiostrepton as an effective nanomedicine for inhibiting tumor
growth and for suppressing FOXM1 in human xenografts. Mol Cancer
Res. 10:2287–2297. 2011.
|
|
49
|
Kwok JM, Peck B, Monteiro LJ, Schwenen HD,
Millour J, Coombes RC, Myatt SS and Lam EW: FOXM1 confers acquired
cisplatin resistance in breast cancer cells. Mol Cancer Res.
8:24–34. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang M and Gartel AL: Combination with
bortezomib enhances the antitumor effects of
nanoparticle-encapsulated thiostrepton. Cancer Biol Ther.
13:184–189. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Jin P, Chen X, Yu G, Li Z, Zhang Q and
Zhang JV: The clinical and experimental research on the treatment
of endometriosis with thiostrepton. Anticancer Agents Med Chem.
19:323–329. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Jiang L, Wu X, Wang P, Wen T, Yu C, Wei L
and Chen H: Targeting FoxM1 by thiostrepton inhibits growth and
induces apoptosis of laryngeal squamous cell carcinoma. J Cancer
Res Clin Oncol. 141:971–981. 2015. View Article : Google Scholar : PubMed/NCBI
|
